AB Science announces the postponement of its annual general shareholders’ meeting
22 Mai 2020 - 6:14PM
AB Science announces the postponement of its annual general
shareholders’ meeting
PRESS RELEASE
POSTPONEMENT OF THE AB SCIENCE ANNUAL
GENERAL SHAREHOLDERS’ MEETING
Paris, France – May 22,
2020
AB Science SA (Euronext - FR0010557264 - AB)
today announces the postponement of its annual general
shareholders’ meeting.
In the exceptional context of the Covid-19
pandemic and in accordance with the ordinances taken on March 25,
2020 by the French Government (and in particular the ordinance n °
2020-318 allowing the extension for three months of the deadline
for approving the annual financial statements), the Board of
Directors, aware of the importance of the annual general meeting
for shareholders and excluding the possibility to organize this
event behind closed doors, has decided to postpone the AB Science
annual general shareholders’ meeting, usually held in June, until a
later date, and in any event no later than September 30, 2020.
The date of the annual general shareholders’
meeting will be communicated later, in accordance with the
provisions in force.
AB Science is committed, as a priority, to
ensuring the health and safety of its shareholders, while
maintaining their participation rights under the best conditions at
its annual general meeting.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, and inflammatory diseases. The
company is headquartered in Paris, France, and listed on Euronext
Paris (ticker: AB).Further information is available on AB Science’s
website: www.ab-science.com.
Forward-looking Statements - AB
Science
This press release contains forward-looking
statements. These statements are not historical facts. These
statements include projections and estimates as well as the
assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial
results, events, operations, future services, product development
and their potential or future performance.These forward-looking
statements can often be identified by the words "expect",
"anticipate", "believe", "intend", "estimate" or "plan" as well as
other similar terms. While AB Science believes these
forward-looking statements are reasonable, investors are cautioned
that these forward-looking statements are subject to numerous risks
and uncertainties that are difficult to predict and generally
beyond the control of AB Science and which may imply that results
and actual events significantly differ from those expressed,
induced or anticipated in the forward-looking information and
statements. These risks and uncertainties include the uncertainties
related to product development of the Company which may not be
successful or to the marketing authorizations granted by competent
authorities or, more generally, any factors that may affect
marketing capacity of the products developed by AB Science, as well
as those developed or identified in the public documents filed by
AB Science with the Autorité des Marchés Financiers (AMF),
including those listed in the Chapter 4 "Risk Factors" of AB
Science reference document filed with the AMF on November 22, 2016,
under the number R. 16-078. AB Science disclaims any
obligation or undertaking to update the forward-looking
information and statements, subject to the applicable regulations,
in particular articles 223-1 et seq. of the AMF General
Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
- AB Science CP report AG VEng VF
Ab Science (EU:AB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ab Science (EU:AB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024